Notably, a favorable trend in PFS was observed even in NETs G3, where treatment options with high levels of evidence are limited, although the difference was not statistically significant.
← all excerpts
Systemic therapy for gastroenteropancreatic neuroendocrine neoplasms: current landscape and future directions.
1
—
—